Abstracts tagged "mycophenolate mofetil and systemic sclerosis"

Abstract Number: 3175 • 2016 ACR/ARHP Annual Meeting
Longitudinal Analysis of MMF Clinical, Molecular, and Immunohistochemistry (IHC) Responses Shows SSc Patients Lose Their Inflammatory Signature and Rebound upon Treatment Cessation
Diana Toledo¹, Monique Hinchcliff², Jaclyn Taroni¹, Tammara A. Wood³, Jennifer Franks³, Sanjiv Shah⁴, Rishi Agrawal⁴, Lauren Beussink-Nelson⁴, Mary A. Carns⁵, Sofia Podlusky⁶, Patricia Pioli⁷ and Michael Whitfield³, ¹Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ³Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Northwestern University, Chicago, IL, ⁵Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁶Rheumatology Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁷Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: We previously showed patients in the inflammatory subset were most likely to demonstrate improvement in modified Rodnan Skin Score (mRSS) during mycophenolate mofetil (MMF)…
Abstract Number: 1076 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Michael Roth², Robert Elashoff³, Philip J. Clements¹, Daniel E. Furst², Dinesh Khanna⁴, Jonathan Goldin⁵, Donald Tashkin¹ and Scleroderma Lung Study II Group, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴Medicine, University of Michigan, Ann Arbor, MI, ⁵David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although cyclophosphamide (CYC) demonstrated beneficial treatment effects at…
Abstract Number: 2962 • 2015 ACR/ARHP Annual Meeting
Efficacy of Mycophenolate As a Maintenance Therapy Following the Administration of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis
Javier Narváez¹, Helena Borrell Paños², Ivan Castellvi³, Sergi Heredia², Milena Millan³, Susana Herrera⁴, Eulalia Armengol², Josep María LLobet³, Joan Miquel Nolla², María Molina⁵ and Juan José Alegre⁶, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, ⁵Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Background/Purpose: Treatment with cyclophosphamide (CYC) for 12 months stabilizes lung function parameters and improves respiratory symptoms of patients with systemic sclerosis and diffuse interstitial lung…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].